Search

Your search keyword '"Lascoux-Combe, Caroline"' showing total 169 results

Search Constraints

Start Over You searched for: Author "Lascoux-Combe, Caroline" Remove constraint Author: "Lascoux-Combe, Caroline" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
169 results on '"Lascoux-Combe, Caroline"'

Search Results

1. Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study

2. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

4. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine

5. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort

6. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort

7. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023.

8. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

9. High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022.

10. HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort

16. Clinical Description of Sixty-Six Cases of Monkeypox Virus (MKPV) Infection Among Men Who Have Sex With Men (MSM) in an HIV/PrEP French Clinic

17. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus–coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13–HEPAVIH Cohort

18. Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort

19. Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers

21. Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

23. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide

24. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings

26. A highly virulent variant of HIV-1 circulating in the Netherlands

27. EFFICACY AND SAFETY OF TREATMENT WITH BULEVIRTIDE IN CHRONIC HEPATITIS DELTA: PRELIMINARY RESULTS OF THE REAL LIFE ANRS HD EP01 BULEDELTA COHORT

28. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression

29. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B Running title: Liver fibrosis evolution in HIV/HBV coinfection

31. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

32. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study

33. Persistent HBV replication and serological response during up to fifteen years of tenofovir-based antiretroviral therapy in HIV-hepatitis B coinfected patients: a multicenter prospective cohort study

34. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus–Hepatitis B Virus–Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort

35. HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection

36. Erratum to: Kinetics of Hepatitis B Core\textendashRelated Antigen and Anti\textendashHepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus\textendashHepatitis B Coinfection

37. Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected patients: a retrospective analysis of a 15-year longitudinal cohort

38. Characterization of HIV-1 diversity in various compartments at the time of primary infection by ultradeep sequencing

39. OS-066 - HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort

40. Liver fibrosis regression and progression during controlled hepatitis b virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study

41. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus–Hepatitis B Virus–Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort.

42. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta

43. Erratum to: Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection

44. Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study (Preprint)

45. Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir

46. Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection

47. HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.

48. Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study

50. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus.

Catalog

Books, media, physical & digital resources